Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Robson

Showing results (11-20 of 218) with videos related to

Pageof 22
Sort By:
Hematology/Oncology Clinics of North America|March 3, 2009
Inherited predisposition to gastrointestinal stromal tumorRinki Agarwal, Mark Robson
Cancer Treatment and Research|November 17, 2023
Clinical Use of PARP Inhibitors in BRCA Mutant and Non-BRCA Mutant Breast CancerFilipa Lynce, Mark Robson
JAMA|August 21, 2019
Broadening Criteria for BRCA1/2 Evaluation: Placing the USPSTF Recommendation in ContextSusan Domchek, Mark Robson
The New England Journal of Medicine|July 13, 2007
Clinical practice. Management of an inherited predisposition to breast cancerMark Robson, Kenneth Offit
JAMA Oncology|October 4, 2019
Broad Application of Multigene Panel Testing for Breast Cancer Susceptibility-Pandora's Box Is Opening WiderMark Robson, Susan Domchek
Hematology/Oncology Clinics of North America|September 7, 2010
Genetic predisposition to cancer. PrefaceKenneth Offit, Mark Robson
Oncology (Williston Park, N.Y.)|March 2, 2010
Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancerElizabeth A Comen, Mark Robson
Cancer Journal (Sudbury, Mass.)|February 19, 2010
Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancerElizabeth A Comen, Mark Robson
Journal of Agromedicine|July 29, 2010
Pesticides and other chemicals: minimizing worker exposuresMatthew Keifer, Frank Gasperini, Mark Robson
Human and Ecological Risk Assessment : HERA|September 2, 2024
A Novel Biomonitoring Method to Detect Pyrethroid Metabolites in Saliva of Occupationally Exposed Workers as a Tool for Risk AssessmentMelody Wren, Mark Robson, Brian Buckley
Pageof 22

Showing results (11-20 of 218) with videos related to

Sort By:
Pageof 22
Hematology/Oncology Clinics of North America|March 3, 2009
Inherited predisposition to gastrointestinal stromal tumorRinki Agarwal, Mark Robson
Cancer Treatment and Research|November 17, 2023
Clinical Use of PARP Inhibitors in BRCA Mutant and Non-BRCA Mutant Breast CancerFilipa Lynce, Mark Robson
JAMA|August 21, 2019
Broadening Criteria for BRCA1/2 Evaluation: Placing the USPSTF Recommendation in ContextSusan Domchek, Mark Robson
The New England Journal of Medicine|July 13, 2007
Clinical practice. Management of an inherited predisposition to breast cancerMark Robson, Kenneth Offit
JAMA Oncology|October 4, 2019
Broad Application of Multigene Panel Testing for Breast Cancer Susceptibility-Pandora's Box Is Opening WiderMark Robson, Susan Domchek
Hematology/Oncology Clinics of North America|September 7, 2010
Genetic predisposition to cancer. PrefaceKenneth Offit, Mark Robson
Oncology (Williston Park, N.Y.)|March 2, 2010
Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancerElizabeth A Comen, Mark Robson
Cancer Journal (Sudbury, Mass.)|February 19, 2010
Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancerElizabeth A Comen, Mark Robson
Journal of Agromedicine|July 29, 2010
Pesticides and other chemicals: minimizing worker exposuresMatthew Keifer, Frank Gasperini, Mark Robson
Human and Ecological Risk Assessment : HERA|September 2, 2024
A Novel Biomonitoring Method to Detect Pyrethroid Metabolites in Saliva of Occupationally Exposed Workers as a Tool for Risk AssessmentMelody Wren, Mark Robson, Brian Buckley
Pageof 22